Evaxion A/S (EVAX)
NASDAQ: EVAX · Real-Time Price · USD
2.945
+0.065 (2.26%)
At close: Sep 12, 2025, 4:00 PM EDT
2.940
-0.005 (-0.17%)
After-hours: Sep 12, 2025, 4:00 PM EDT
Evaxion Employees
Evaxion had 46 employees as of December 31, 2024. The number of employees decreased by 3 or -6.12% compared to the previous year.
Employees
46
Change (1Y)
-3
Growth (1Y)
-6.12%
Revenue / Employee
$69,043
Profits / Employee
-$260,304
Market Cap
18.60M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 46 | -3 | -6.12% |
| Dec 31, 2023 | 49 | -14 | -22.22% |
| Dec 31, 2022 | 63 | 2 | 3.28% |
| Dec 31, 2021 | 61 | 26 | 74.29% |
| Dec 31, 2020 | 35 | -1 | -2.78% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
EVAX News
- 26 days ago - Evaxion A/S (EVAX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025 - GlobeNewsWire
- 7 weeks ago - Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 - GlobeNewsWire
- 2 months ago - Evaxion finalizes agreement with EIB to convert debt into equity - GlobeNewsWire
- 2 months ago - Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio - GlobeNewsWire
- 2 months ago - Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus - GlobeNewsWire
- 3 months ago - Evaxion receives grant funding to design new polio vaccine - GlobeNewsWire
- 3 months ago - Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha